Table 1.
Day of Pregnancy | No. of determinations | Chain length:number of double bonds, pmol/μmol lipid phosphorus, mean ± SD
|
|||||
---|---|---|---|---|---|---|---|
16:0 | 18:0 | 18:1n-9 | 18:1n-7 | 18:2n-6 | 20:4n-6 Anandamide* | ||
1 | 2 | 10.8 ± 1.2 | 11.0 ± 0.1 | 43.6 ± 21.9 | 1.3 ± 0.9 | 0.6 ± 0.4 | 289 ± 17.6 |
2 | 2 | 9.7 ± 0.0 | 11.5 ± 0.7 | 13.4 ± 0.1 | 1.8 ± 0.1 | 0.4 ± 0.4 | 428 ± 32.1 |
3 | 2 | 12.2 ± 1.3 | 13.4 ± 1.1 | 8.8 ± 2.2 | 3.2 ± 0.9 | 0.5 ± 0.3 | 566 ± 160.2 |
4 | 3 | 10.1 ± 0.7 | 8.8 ± 1.3 | 12.0 ± 3.7 | 1.9 ± 0.4 | 0.7 ± 0.4 | 345 ± 66.0 |
4, pseudopregnant | 2 | 11.6 ± 0.04 | 9.6 ± 0.7 | 10.6 ± 4.0 | 0.9 ± 0.6 | 0.8 ± 0.6 | 509 ± 12.2 |
5, pseudopregnant | 3 | 11.1 ± 1.0 | 11.6 ± 0.4 | 15.8 ± 4.3 | 1.9 ± 0.9 | 1.0 ± 0.4 | 937 ± 13.8 |
5, implant sites | 3 | 15.7 ± 0.03 | 7.5 ± 10.7 | 5.8 ± 0.3 | 1.9 ± 0.2 | 1.4 ± 0.03 | 142 ± 1.7 |
5, interimplant sites | 3 | 8.0 ± 1.1 | 11.6 ± 1.6 | 3.5 ± 0.8 | 2.1 ± 0.4 | 0.8 ± 0.1 | 583 ± 5.0 |
7, implant sites | 3 | 17.1 ± 0.2 | 38.1 ± 4.2 | 8.9 ± 1.3 | 4.1 ± 0.5 | 1.3 ± 0.5 | 330 ± 68.5 |
7, interimplant sites | 3 | 21.2 ± 0.9 | 18.1 ± 2.3 | 40.0 ± 12.0 | 1.4 ± 1.0 | 1.8 ± 0.9 | 1,345 ± 140.0 |
NAEs, isolated by TLC from lipid extracts of whole uteri, implantation sites, or interimplantation sites on indicated days of pseudopregnancy or pregnancy were analyzed by GC-MS. Levels of anandamide in day 5 pseudopregnant uteri were significantly higher (P < 0.05) from those on days 1–4 of pregnancy or pseudopregnancy (ANOVA followed by Student’s t-test). Level of anandamide in interimplantation sites were significantly higher (P < 0.05) than those from implantation sites (paired t-test).
Other polyunsaturated NAEs may also be present but were not included in this assay.